PL370407A1 - Processes for preparing calcium salt forms of statins - Google Patents

Processes for preparing calcium salt forms of statins

Info

Publication number
PL370407A1
PL370407A1 PL02370407A PL37040702A PL370407A1 PL 370407 A1 PL370407 A1 PL 370407A1 PL 02370407 A PL02370407 A PL 02370407A PL 37040702 A PL37040702 A PL 37040702A PL 370407 A1 PL370407 A1 PL 370407A1
Authority
PL
Poland
Prior art keywords
statins
processes
calcium salt
salt forms
preparing calcium
Prior art date
Application number
PL02370407A
Other languages
Polish (pl)
Inventor
Valerie Niddam-Hildesheim
Revital Lifshitz-Liron
Rami Lidor-Hadas
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/037,412 external-priority patent/US6528661B2/en
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of PL370407A1 publication Critical patent/PL370407A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
PL02370407A 2001-08-16 2002-08-16 Processes for preparing calcium salt forms of statins PL370407A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31281201P 2001-08-16 2001-08-16
US10/037,412 US6528661B2 (en) 2000-11-16 2001-10-24 Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide

Publications (1)

Publication Number Publication Date
PL370407A1 true PL370407A1 (en) 2005-05-30

Family

ID=26714105

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02370407A PL370407A1 (en) 2001-08-16 2002-08-16 Processes for preparing calcium salt forms of statins

Country Status (17)

Country Link
EP (1) EP1425287A4 (en)
JP (2) JP4188826B2 (en)
CN (1) CN100430405C (en)
AU (1) AU2002324715B2 (en)
CA (1) CA2450820C (en)
CZ (1) CZ2004337A3 (en)
HR (1) HRPK20040255B3 (en)
HU (1) HUP0500616A3 (en)
IL (2) IL160077A0 (en)
IS (1) IS7148A (en)
MX (1) MXPA04001451A (en)
NO (1) NO20041082L (en)
NZ (1) NZ529913A (en)
PL (1) PL370407A1 (en)
SK (1) SK1402004A3 (en)
TR (1) TR200302281T2 (en)
WO (1) WO2003016317A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CA2427255A1 (en) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
HUP0500074A3 (en) 2002-03-18 2005-07-28 Biocon Ltd Bangalore Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
EP1585736A2 (en) * 2002-05-21 2005-10-19 Ranbaxy Laboratories, Ltd. Process for the preparation of rosuvastatin
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE202004021379U1 (en) * 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Crystalline forms of pitivastatin calcium
SI1631533T1 (en) 2003-04-22 2009-08-31 Bicon Ltd Novel process for stereoselective reduction of beta-ketoesters
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
BRPI0412786A (en) 2003-07-25 2006-09-26 Avecia Pharmaceuticals Ltd process for preparing a compound, and, compound
AU2003269477A1 (en) * 2003-08-26 2005-03-10 Biocon Limited Novel process for preparation of 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3, 5-dihydroxy-6-heptenoic acid sodium salt
WO2005023778A2 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
EP1816126A1 (en) * 2003-08-28 2007-08-08 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
UY28501A1 (en) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd CHEMICAL COMPOUNDS
WO2005026107A1 (en) 2003-09-18 2005-03-24 Biocon Limited Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
EP1678148A1 (en) * 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1601658A1 (en) 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
JP2007517028A (en) * 2003-12-29 2007-06-28 レツク・フアーマシユーテイカルズ・デー・デー Amorphous (4R-cis) -6- [2- [3-phenyl-4- (phenylcarbamoyl) -2- (4-fluorophenyl) -5- (1-methylethyl) -pyrrol-1-yl ] -Ethyl] -2,2-dimethyl- [1,3] -dioxan-4-yl-acetic acid
CZ200486A3 (en) * 2004-01-16 2005-08-17 Zentiva, A.S. Process for preparing hemicalcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
SI21745A (en) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polymorphs of 1-pyrrol-1-heptanoic acid derivative, intermediat for preparation of atorvastatin
WO2006017357A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
JP2008509154A (en) * 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド Novel statin drug compositions and related treatment methods
KR101020024B1 (en) 2005-02-22 2011-03-09 테바 파마슈티컬 인더스트리즈 리미티드 Rosuvastatin and salts thereof containing no rosuvastatin alkyl ether and preparation method thereof
CZ299215B6 (en) * 2005-06-29 2008-05-21 Zentiva, A. S. Process for preparing hemi-calcium salt of rosuvastatin, i.e. (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid
CA2617805A1 (en) * 2005-08-04 2007-02-15 Transform Pharmaceuticals, Inc. Novel formulations comprising fenofibrate and a statin, and related methods of treatment
WO2007022488A2 (en) 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
CN100371709C (en) * 2005-12-12 2008-02-27 重庆医药工业研究院有限责任公司 A method for separating and measuring pitavastatin and its optical isomers by liquid chromatography
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2022784A1 (en) 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
HUP1000299A2 (en) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation
EP3178812A1 (en) * 2010-11-12 2017-06-14 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN102875504A (en) * 2011-07-13 2013-01-16 华南理工大学 Application of 4,5,6,7-tetrahydro pravastatin and salts thereof in cardiovascular diseases
CN102302452B (en) * 2011-09-14 2012-11-21 海南美大制药有限公司 Pitavastatin calcium lipid solid preparation
CN102796036B (en) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 Preparation method of atorvastatin calcium
CN103724278B (en) * 2013-12-12 2019-03-29 江苏阿尔法药业有限公司 The preparation method of Statins intermediate and its derivative
US9695130B2 (en) 2014-02-06 2017-07-04 Api Corporation Rosuvastatin calcium and process for producing intermediate thereof
KR20160126700A (en) 2015-04-24 2016-11-02 미래파인켐 주식회사 New Statin intermediate, the preparation of the same and the preparation of Rosuvastatin using the same
CN105017231B (en) * 2015-06-26 2018-01-26 上海应用技术学院 Multi-substituted indole statin fluorine-containing modification and use thereof
CN105111173B (en) * 2015-06-26 2017-06-23 上海应用技术学院 Statin fluorine-containing derivant and application thereof
CN107949556B (en) 2015-08-05 2021-12-07 株式会社Api Method for producing pitavastatin calcium
CN111362856B (en) * 2020-04-29 2023-08-18 福建海西新药创制股份有限公司 Method for producing atorvastatin calcium by utilizing micro-reaction device

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5817443B2 (en) * 1976-11-02 1983-04-07 三共株式会社 Hyperlipidemia therapeutic agent whose main ingredient is ML-236B metal salt
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
KR100389518B1 (en) * 1995-07-17 2003-11-15 워너-램버트 캄파니 엘엘씨 Crystalline [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Hemi Calcium Salt(Atorvastatin)
US5669156A (en) * 1996-08-28 1997-09-23 Fleetwood Systems, Inc. Can end curing system with magnetic fanning and belt conveying
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
CA2364253A1 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
CA2427255A1 (en) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
AU2007205725A1 (en) * 2000-11-30 2007-08-30 Teva Pharmaceutical Industries Ltd. Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2003018547A2 (en) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)

Also Published As

Publication number Publication date
WO2003016317A1 (en) 2003-02-27
CN100430405C (en) 2008-11-05
MXPA04001451A (en) 2005-02-17
IL160077A (en) 2007-10-31
CN1543468A (en) 2004-11-03
HRPK20040255B3 (en) 2006-02-28
SK1402004A3 (en) 2005-01-03
IL160077A0 (en) 2004-06-20
IS7148A (en) 2004-02-11
TR200302281T2 (en) 2004-09-21
CA2450820A1 (en) 2003-02-27
JP2005500382A (en) 2005-01-06
NZ529913A (en) 2005-03-24
CZ2004337A3 (en) 2005-01-12
JP4188826B2 (en) 2008-12-03
HUP0500616A3 (en) 2011-07-28
AU2002324715B2 (en) 2009-03-12
NO20041082L (en) 2004-03-15
JP2009024008A (en) 2009-02-05
EP1425287A1 (en) 2004-06-09
HRP20040255A2 (en) 2004-08-31
EP1425287A4 (en) 2005-09-07
CA2450820C (en) 2011-03-15
HUP0500616A2 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
HUP0500616A3 (en) Processes for preparing calcium salt forms of statins
IL166626A0 (en) Process for preparing the calcium salt of rosuvastatin
IL173858A0 (en) Process for preparation of rosuvastatin calcium
SI1390023T1 (en) Pharmaceutical salts of 1-phenyl-3-dimethylamino-propane compounds
AP2002002550A0 (en) Chiral salt resolution
NZ523557A (en) Calcium salt of valsartan
ZA200409981B (en) Novel formate salt of O-desmethyl-venlafaxine
IL159626A0 (en) Crystalline forms of atorvastatin calcium and processes for the preparation thereof
PL367278A1 (en) Method for inhibiting calcium salt scale
PL367302A1 (en) Method for inhibiting calcium salt scale
IL161086A0 (en) Method for preparing benzenesulfonyl compounds
EP1572638A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF AMORPHOUS CALCIUM ATORVASTATIN SALT (2: 1)
PL355958A1 (en) Application of statins for inhibiting formation of osteoclasts
IL143106A (en) Process for the preparation of diphenylmethylthioacetamide
SI1423360T1 (en) Process for the preparation of cilastatin
HUP0500644A3 (en) Method of synthesizing phenol-containing compounds
IL159355A0 (en) Process for the preparation of nitrile compounds
IL161386A0 (en) Bone anti-resorptive compounds
HUP0302313A3 (en) Co-retarding agents for preparing purified brine
HUP0303123A3 (en) Method of purifying pravastatin or its pharmacologically acceptable salt
SG108831A1 (en) Process for preventing formation of scale
HUP0303025A3 (en) Process for the preparation of arylethanoldiamines
PL368905A1 (en) Process for the preparation of beta-ionylideneacetaldehyde
AU2002329110A1 (en) Method for preparing calcium gluconate
SI1395580T1 (en) Method for the purification of triazolylmethylepoxides

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)